Cargando…
A targeted therapy for melanoma by graphene oxide composite with microRNA carrier
BACKGROUND: Nowadays, the combination of microRNA (miR) is attracting increased attention in clinical cancer trials. However, the clinical use of miR is highly limited because of certain properties such as instability, low-specificity distribution, and metabolic toxicity. METHODS: In order to improv...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157538/ https://www.ncbi.nlm.nih.gov/pubmed/30275686 http://dx.doi.org/10.2147/DDDT.S160088 |
_version_ | 1783358285787693056 |
---|---|
author | Liu, Can Xie, Huiqing Yu, Jingang Chen, Xiaoqing Tang, Shijie Sun, Lichun Chen, Xiang Peng, Defei Zhang, Xiangyan Zhou, Jianda |
author_facet | Liu, Can Xie, Huiqing Yu, Jingang Chen, Xiaoqing Tang, Shijie Sun, Lichun Chen, Xiang Peng, Defei Zhang, Xiangyan Zhou, Jianda |
author_sort | Liu, Can |
collection | PubMed |
description | BACKGROUND: Nowadays, the combination of microRNA (miR) is attracting increased attention in clinical cancer trials. However, the clinical use of miR is highly limited because of certain properties such as instability, low-specificity distribution, and metabolic toxicity. METHODS: In order to improve the anti-tumor efficacy and reduce the side effects of miR in treating melanoma, a combination of graphene oxide (GO), chitosan (CS), and a cellular penetrating peptide, MPG, was prepared with solid dispersion method in this research. The research has analyzed the specific components of nano drug-loading complexes GO-CS and GO-CS-MPG through characterization research and confirmed the bio-safety of the carrier material GO-CS-MPG. RESULTS: The GO-CS-MPG-miR33a/miR199a nano drug-loading complex was successfully constructed and its medical effectiveness was verified. Through the subcutaneous tumor implantation experiment, an evident effect of the drug-loading complex in inhibiting melanoma cells was proven. CONCLUSION: Results suggest that GO-CS-MPG may have potential applications in melanoma therapy. |
format | Online Article Text |
id | pubmed-6157538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61575382018-10-01 A targeted therapy for melanoma by graphene oxide composite with microRNA carrier Liu, Can Xie, Huiqing Yu, Jingang Chen, Xiaoqing Tang, Shijie Sun, Lichun Chen, Xiang Peng, Defei Zhang, Xiangyan Zhou, Jianda Drug Des Devel Ther Original Research BACKGROUND: Nowadays, the combination of microRNA (miR) is attracting increased attention in clinical cancer trials. However, the clinical use of miR is highly limited because of certain properties such as instability, low-specificity distribution, and metabolic toxicity. METHODS: In order to improve the anti-tumor efficacy and reduce the side effects of miR in treating melanoma, a combination of graphene oxide (GO), chitosan (CS), and a cellular penetrating peptide, MPG, was prepared with solid dispersion method in this research. The research has analyzed the specific components of nano drug-loading complexes GO-CS and GO-CS-MPG through characterization research and confirmed the bio-safety of the carrier material GO-CS-MPG. RESULTS: The GO-CS-MPG-miR33a/miR199a nano drug-loading complex was successfully constructed and its medical effectiveness was verified. Through the subcutaneous tumor implantation experiment, an evident effect of the drug-loading complex in inhibiting melanoma cells was proven. CONCLUSION: Results suggest that GO-CS-MPG may have potential applications in melanoma therapy. Dove Medical Press 2018-09-21 /pmc/articles/PMC6157538/ /pubmed/30275686 http://dx.doi.org/10.2147/DDDT.S160088 Text en © 2018 Liu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Liu, Can Xie, Huiqing Yu, Jingang Chen, Xiaoqing Tang, Shijie Sun, Lichun Chen, Xiang Peng, Defei Zhang, Xiangyan Zhou, Jianda A targeted therapy for melanoma by graphene oxide composite with microRNA carrier |
title | A targeted therapy for melanoma by graphene oxide composite with microRNA carrier |
title_full | A targeted therapy for melanoma by graphene oxide composite with microRNA carrier |
title_fullStr | A targeted therapy for melanoma by graphene oxide composite with microRNA carrier |
title_full_unstemmed | A targeted therapy for melanoma by graphene oxide composite with microRNA carrier |
title_short | A targeted therapy for melanoma by graphene oxide composite with microRNA carrier |
title_sort | targeted therapy for melanoma by graphene oxide composite with microrna carrier |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157538/ https://www.ncbi.nlm.nih.gov/pubmed/30275686 http://dx.doi.org/10.2147/DDDT.S160088 |
work_keys_str_mv | AT liucan atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT xiehuiqing atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT yujingang atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT chenxiaoqing atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT tangshijie atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT sunlichun atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT chenxiang atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT pengdefei atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT zhangxiangyan atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT zhoujianda atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT liucan targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT xiehuiqing targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT yujingang targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT chenxiaoqing targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT tangshijie targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT sunlichun targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT chenxiang targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT pengdefei targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT zhangxiangyan targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier AT zhoujianda targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier |